We evaluated a nonisotopic method (cEDIA; cloned enzyme donor immunoassay) for estimating vitamin B12and folate in serum. The assays were performed with a Cobas-Miraanalyzer. intra-assay CVs were from3.7% to 11.0% for vitamin B12 and from 1.2% to 10.7% for folate. lnterassay CVs ranged from 9.5% to 11.9% for vitamin B12 and from 6.1% to 18.5% for folate. Linearity was satisfactory, with analytical recovery of 94% at 8.7 and 25.4 nmol/L for folate and 280 and 554 pmol/L for vitamin B12.The detection limitwas 3.6 nmol/L for folate and 12.3 pmol/L for vitamin B12. Results of this assay correlated well with those of a conventional radioassay: r = 0.98 for vitamin B12 (n = 51) and r = 0.97 for folate (n = 57). The CEDIA was easy to perform but appeared to be unreliable for use with samples from myeloma patients. We studied selected patients' samples that were routinely analyzed for vitamin B, and folate. CEDIA and radioassay reagents were reconstituted according to the suppliers' instructions with one slight modification. Serum samples, standards, and controls were diluted with pretreatment reagent and boiled for 20 mm to destroy the binding proteins. After cooling, the boiled samples were centrifuged (1200 x g, 15 mm, 4#{176}C), and the clear supernate was used. (The kit instructions recommended centrifuging for 5 mm at 8000 x g. To make the CEDIA kit more accessible for smaller hospital laboratories, we decided to examine the possibility of using a lower centrifugal force and a longer centrifugation time. In our hands, 15 mm at 1200 x g was satisfactory.) The CEDIA was performed at 37#{176}C according to the settings recommended by the manufacturer.
Reliable detection of vitamin B12 and folate in serum is important because deficiencies of these nutrients lead to disturbances of normal DNA synthesis and erythrocyte formation (1). Numerous tests, almost all dualradioisotope assays,have been developed for quantitative detection of vitamin B12 and folate in serum (e.g., 2). We studied the performance of the nonisotopic cloned enzyme donor immunoassay (CEDIA) for determining vitamin B12 and folateconcentrations in serum and compared the results with those of a competitive-protein-binding radioassay. We studied selected patients' samples that were routinely analyzed for vitamin B, and folate. CEDIA and radioassay reagents were reconstituted according to the suppliers' instructions with one slight modification. Serum samples, standards, and controls were diluted with pretreatment reagent and boiled for 20 mm to destroy the binding proteins. After cooling, the boiled samples were centrifuged (1200 x g, 15 mm, 4#{176}C), and the clear supernate was used. (The kit instructions recommended centrifuging for 5 mm at 8000 x g. To make the CEDIA kit more accessible for smaller hospital laboratories, we decided to examine the possibility of using a lower centrifugal force and a longer centrifugation time. In our hands, 15 mm at 1200 x g was satisfactory.) The CEDIA was performed at 37#{176}C according to the settings recommended by the manufacturer.
The radioassay was also performed according to the instructions of the manufacturer.
The serum samples were stored at -20 #{176}C until analysis. In a typical CEDIA, three calibrators, containing vitamin B,2 at 21,559, and 1107 pmolIL or folate at 0, 25.2, and 50.8 nmolfL, and as many as 90 patients' samples were analyzed.
Results

Precision.
Intra-assay
CVs for the vitamin B,2 and folate assays are shown in Table 1 . Interassay CVs over a two-week period (10 series) are shown in Table 2 .
Correlation.
Vitamin B,2 in 51 samples and folatein The CEDIA for vitamin B12 appeared to be unreliable for serum samples from myeloma patients. In about half of the samples (4/7), we found a marked discrepancy between the radioassay and the CEDIA (Table 3) .
Discussion
The principle of the CEDIA is well established. It has already been applied for determining digoxin (4, 5), vitamins, hormones, and tumor markers (6).
We investigated the CEDIA for vitamin B,2 and folate and compared our results with the conventional radioassay. The results from the nomsotopic assay correlated closely with those from the radioassay for both vitamin B12 and folate. The correlation was excellent over the clinically relevant range. With the Cobas-Mira, the CEDIA method was easy to handle. Series of as many as 100 tests could be analyzed in one run because of the kit size. With a detection limit of 12.3 pmol/L for vitamin B,2, the CEDIA surpassed the radioassay in sensitivity. Intra-assay and interassay CV studies showed that the CEDIA is comparable with the currently available methods. The intercepts and slopes for the correlations of the methods may be caused by differences in standardization, standards, or (most likely) matrix and binding characteristics. (7) recently reported the same phenomenon. When radioassay standards of vitamin B,2 were measured in the nonisotopic assay, the measured amounts were always greater than the expected values. It is tempting to speculate that vitamin B,2 is released more easily from a syntheticmatrix (in standards) than from the endogenous matrix (in serum).
Fu and Heshemi
The only drawback of the CEDIA system is itsfailureto reliably measure vitamin B,2 in serum from myeloma patients. We came across this phenomenon by chance.
In our series of patients' samples for the correlation study, there was one sample from a myelorna patient (IgG K). We found a large difference between the two methods for this sample. In a preliminary experiment we selectedseven different myeloma samples, as indicated in Table 3 . In about half of the samples we found a marked discrepancy between the assays: values from the CEDIA were higher (as much as 17-fold) and lower (fourfold) than the measured values in the radioassay.
From hematological
indexes and the peripheral blood smear, we concluded that these patients should have had normal values for vitamin B,2, and therefore it is likely that the CEDIA failed in these cases. As mentioned in the kit instructions, gamma globulins added to serum with a normal albumin concentration do not disturb the assay up to a total protein concentration of 100 g/L.In severe myeloma, the protein concentration is sometimes much higher. It also is possible that M components have an affinity for substances in the assay, which may contribute to the problems we found. Because protein concentrations can be decreased and increased in myeloma samples, we conclude that the CEDIA is not suitable for determining vitamin B12in these samples.
The priceof a CEDIA determination of vitamin B,2 and folate is -$8.50 per sample, whereas the radioassay costs -$3.50. Advantages of the CEDIA over the radioassay are that laboratory personnel are not exposed to ionizing radiation from the radionucides used, duplicates of samples can be run simultaneously, the analysis is much faster (twofold), and the technique is applicable for routine use in laboratories without a radioactivity license.
